Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Anokion is raising $35,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Deborah Geraghty played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Anokion
Anokion SA is a Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal immune tolerance. The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes. Anokions distinct approach leverages the company’s immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the underlying cause of autoimmune disease.

To learn more about Anokion, visit http://www.anokion.com/

Contact:
Deborah Geraghty, Chief Executive Officer
857-320-6607

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved